Market Research Report

Global Cyanotic Heart Disease Market Research Report: Forecast (2023-2028)

By Treatment Type (Medication, Surgery), By Route of Administration (Oral, Parenteral, Others), By End Users (Hospitals, Homecare, Speciality Centres, Others), By Distribution Chan...nel (Hospital, Pharmacy), By Region (North America, South America, Europe, The Middle East & Africa, Asia-Pacific), By Company (Cipla Inc, Amneal Pharmaceutical LLC, Bausch Health Companies Inc., Pfizer Inc, Hikma Pharmaceuticals Plc, Eton Biotech Pvt. Ltd, Norvartis AG, Johnsons & Johnsons Services Inc, Teva Pharmaceutical Industries Ltd., Other) Read more

  • Healthcare
  • Aug 2023
  • 194
  • HC22129

Market Definition

Cyanotic heart disease is a subgroup of congenital heart defects resulting in decreased blood oxygen levels. These defects create abnormal connections between the heart's chambers or blood vessels, mixing oxygen-poor blood with oxygen-rich blood.

Market Insights & Analysis: Global Cyanotic Heart Disease Market (2023-28)

The Global Cyanotic Heart Disease Market size is projected to grow at a CAGR of around 8.6% during the forecast period, i.e., 2023-28. The market growth primarily attributes to intensifying cases of congenital heart diseases, particularly CCHD, that can lead to severe health problems or death if not treated promptly.

  • Congenital heart disease (CHD) affects around 8 to 9 out of every 1000 live births. Of these cases, roughly 25% are classified as critical CHDs. In the United States alone, it's estimated that approximately 7,200 babies are born each year with these severe heart conditions.
Report Coverage Details
Study Period Historical Data: 2018-21
Base Year: 2022
Forecast Period: 2023-28
CAGR (2023-2028) 8.6%
Regions Covered North America: US, Canada, Mexico
Europe: Germany, The UK, France, Spain, Italy, Rest of Europe
Asia-Pacific: China, India, Japan, South Korea, Australia, Rest of Asia-Pacific
South America: Brazil, Argentina, Rest of South America
Middle East & Africa: UAE, Saudi Arabia, Qatar, Egypt, South Africa, Rest of the Middle East & Africa
Key Companies Profiled Cipla Inc, Amneal Pharmaceutical LLC, Bausch Health Companies Inc., Pfizer Inc, Hikma Pharmaceuticals Plc, Eton Biotech Pvt. Ltd, Norvartis AG, Johnsons & Johnsons Services Inc, Teva Pharmaceutical Industries Ltd., Other
Unit Denominations USD Million/Billion

 

Recent years have witnessed numerous advancements in medical technology and diagnostic techniques to achieve the early detection & diagnosis of cyanotic heart conditions, leading to increased demand for treatments & interventions in the market. Several research & development efforts by pharmaceutical & medical device companies have led to the introduction of innovative therapies & devices, i.e., driving market expansion. Besides, the rising awareness and improved access to healthcare services are allowing more & more patients to seek medical attention, consequently contributing to market growth.

Global Cyanotic Heart Disease Market Driver:

Rising Prevalence of Critical Congenital Heart Disease Worldwide- The market for cyanotic heart disease is largely influenced by factors such as the prevalence of the condition, followed by the level of awareness and advancements in diagnostic techniques. The increasing number of individuals affected can have a significant impact on the demand for related medications, devices, and treatment options. With greater awareness of cyanotic heart disease, more individuals can recognize its symptoms and seek medical attention. Moreover, advancements in diagnostic techniques lead to earlier and more accurate diagnoses, prompting a higher number of patients to seek timely treatment, further affecting the cyanotic heart disease market dynamics.


Global Cyanotic Heart Disease Market Research Report: Forecast (2023-2028)

Global Cyanotic Heart Disease Market Trend:

Newborn Screening for Critical Congenital Heart Disease (CCHD) Using Pulse Oximetry- Newborn screening using Pulse Oximetry has gained global momentum, now integrated into uniform screening panels in many countries. Identifying CCHD early allows for timely surgical intervention, boosting infant survival chances. As a result, Governments worldwide, driven by the rising rank of CHD as a contributor to infant mortality, are increasingly adopting this screening to reduce overall infant mortality rates.

  • The Secretary for Health and Human Services has nationally endorsed screening for Critical Congenital Heart Disease (CCHD), while the American Heart Association, American Academy of Pediatrics, and American College of Cardiology have given their endorsement specifically to pulse oximetry screening for CCHD.

Global Cyanotic Heart Disease Market (2023-28): Segmentation Analysis

The Global Cyanotic Heart Disease Market study from MarkNtel Advisors evaluates & highlights the major trends & influencing factors in each segment & includes predictions for the period 2023–2028 at the global, regional, and national levels. Based on the analysis, the market has been further classified as:

Based on the Treatment Type:

  • Medication
  • Surgery

Of both, surgery holds a considerable share in the Global Cyanotic Heart Disease Market. The most notable trend in the market is the rapid development & adoption of minimally invasive procedures. Traditional treatment approaches for cyanotic heart diseases often involve complex, high-risk open-heart surgeries. However, with advancements in medical technology & surgical techniques, minimally invasive procedures have garnered massive popularity, as they involve reduced risks, shorter recovery times, and improved patient outcomes, i.e., contributing to their growing adoption by both patients & healthcare providers.

Based on End Users:

  • Hospitals
  • Homecare
  • Specialty Centres

Here, hospitals acquired a larger market share in 2022, and the same dominance is likely during 2023-28. It ascribes to their critical role in providing specialized care & treatment for patients with CCHD. These healthcare facilities offer extensive services, encompassing surgeries, diagnostics, & emergency care, which make them the preferred option for patients with severe conditions.

On the other hand, home care is increasingly gaining popularity as a viable alternative, especially for patients requiring ongoing, long-term management & monitoring of their condition from their homes. Other types of healthcare facilities & providers may contribute to the market by offering supplementary services or support to patients with cyanotic heart disease, creating a diverse landscape for addressing the healthcare needs of affected individuals.

Global Cyanotic Heart Disease Market Regional Projection:

Geographically, the Global Cyanotic Heart Disease Market expands across:

  • North America
  • South America
  • Europe
  • Middle East & Africa
  • Asia-Pacific

Of all regions globally, North America, particularly the US, holds the dominant position in the Cyanotic Heart Disease Market. The country witnesses significant instances of cyanotic heart disease, which has instigated the government to intervene with numerous research & health initiatives in order to address its impact on individuals. Newborn Screening for critical congenital heart disease (CCHD) is now widely practiced across the region, and related guidelines have been issued nationwide to help detect & care for infants with CHD as early as possible. This has compelled many high-income countries to adopt similar screening programs in a bid to address the burden of CHD, particularly cyanotic heart disease.

On the other hand, recognizing that addressing mortality from CHD can significantly impact overall infant mortality & under-five mortality rates, various countries in the Asia Pacific region, particularly middle-income & upper-middle-income nations, have set national & subnational goals to reduce these rates. Newborn Screening for CCHD is seen as a critical tool in achieving these objectives, as it allows for the timely diagnosis & intervention for affected infants, i.e., driving the market expansion.

Global Cyanotic Heart Disease Industry Recent Developments:

  • In May 2023, Teva Pharmaceutical Industries Ltd. revealed its latest strategic plan, consisting of four key pillars. The primary goal of this approach is to prepare the Company for a new phase of expansion. The strategy involves strengthening the Company's commercial portfolio by leveraging AUSTEDO®, AJOVY®, UZEDYTM, and biosimilars while boosting its innovative pipeline. These four pillars are expected to generate more value and significantly benefit patients.

Gain a Competitive Edge with Our Global Cyanotic Heart Disease Market Report

  1. Global Cyanotic Heart Disease Market report provides a detailed and thorough analysis of market size, growth rate, competitive landscape, and key players. This comprehensive analysis helps businesses gain a holistic understanding of the market dynamics and make informed decisions.
  2. This report also highlights current market trends and future projections, allowing businesses to identify emerging opportunities and potential challenges. By understanding market forecasts, companies can align their strategies and stay ahead of the competition.
  3. Global Cyanotic Heart Disease Market analysis aids in assessing and mitigating risks associated with entering or operating in the industry.
  4. The report would help in understanding market dynamics, regulatory frameworks, and potential challenges, businesses can develop strategies to minimize risks and optimize their operations.

Frequently Asked Questions

   A. The Cyanotic Heart Disease Market growth rate or CAGR is expected to be around 8.6% during 2023-28.

   A. The mounting prevalence of critical congenital heart diseases worldwide is the prime aspect projected to drive the Cyanotic Heart Disease Market through 2028.

   A. Hospitals are anticipated to emerge as an area of remunerative opportunities for the leading players in the Cyanotic Heart Disease Market during the forecast period.

   A. Cipla Inc, Amneal Pharmaceutical LLC, Bausch Health Companies Inc., Pfizer Inc., Hikma Pharmaceuticals Plc, Eton Biotech Pvt. Ltd, Norvartis AG, Johnsons & Johnsons Services Inc., and Teva Pharmaceutical Industries Ltd. are the major shareholders in the Cyanotic Heart Disease Market.

   A. Globally, North America would provide lucrative prospects for the Cyanotic Heart Disease Market leaders in the years ahead.

   A. Newborn screening for critical congenital heart disease (CCHD) using pulse oximetry is the significant trend projected to shape the Cyanotic Heart Disease Market through 2028.

Global Yanotic Heart Disease Market Research Report (2023-2028) - Table of Contents

 

  1. Introduction
    1. Product Definition
    2. Research Process
    3. Assumptions
  2. Market Segmentation
  3. Executive Summary
  4. Global Cyanotic Heart Disease Market Regulations, Norms, & Product Standards
  5. Global Cyanotic Heart Disease Market Trends & Developments
  6. Global Cyanotic Heart Disease Market Dynamics
    1. Drivers
    2. Challenges
  7. Global Cyanotic Heart Disease Market Imports, Exports Statistics
  8. Global Cyanotic Heart Disease Market Hotspots & Opportunities
  9. Global Cyanotic Heart Disease Market Value Chain & Stakeholder Margin Analysis
  10. Global Cyanotic Heart Disease Market Analysis (2018-2028F)
    1. Market Size & Analysis
      1. Market Revenues (USD Million)
    2. Market Share & Analysis
      1. By Treatment Type
        1. Medication
        2. Surgery
      2. By Route of Administration
        1. Oral
        2. Parenteral
        3. Others
      3. By End Users
        1. Hospitals
        2. Homecare
        3. Speciality Centres
        4. Others
      4. By Distribution Channel
        1. Hospital
        2. Pharmacy
          1. Online Pharmacy
          2. Retail Pharmacy
      5. By Company
        1. Revenue Shares
        2. Competition Characteristics
      6. By Region
        1. North America
        2. South America
        3. Europe
        4. The Middle East & Africa
        5. Asia-Pacific
  11. North America Cyanotic Heart Disease Market Analysis (2018-2028F)
    1. Market Size & Analysis
      1. Market Revenues (USD Million)
    2. Market Share & Analysis
      1. By Treatment Type- Market Size & Forecast 2018-2028F, USD Million
      2. By Route of Administration- Market Size & Forecast 2018-2028F, USD Million
      3. By End Users- Market Size & Forecast 2018-2028F, USD Million
      4. By Distribution Channel- Market Size & Forecast 2018-2028F, USD Million
      5. By Company- Market Size & Forecast 2018-2028F, USD Million
      6. By Country
        1. The US
        2. Canada
        3. Mexico
    3. The US Cyanotic Heart Disease Market Analysis (2018-2028F)
      1. By Treatment Type- Market Size & Forecast 2018-2028F, USD Million
      2. By End Users- Market Size & Forecast 2018-2028F, USD Million
    4. Canada Cyanotic Heart Disease Market Analysis (2018-2028F)
      1. By Treatment Type- Market Size & Forecast 2018-2028F, USD Million
      2. By End Users- Market Size & Forecast 2018-2028F, USD Million
    5. Mexico Cyanotic Heart Disease Market Analysis (2018-2028F)
      1. By Treatment Type- Market Size & Forecast 2018-2028F, USD Million
      2. By End Users- Market Size & Forecast 2018-2028F, USD Million
  12. South America Cyanotic Heart Disease Market Analysis (2018-2028F)
    1. Market Size & Analysis
      1. Market Revenues (USD Million)
    2. Market Share & Analysis
      1. By Treatment Type- Market Size & Forecast 2018-2028F, USD Million
      2. By Route of Administration- Market Size & Forecast 2018-2028F, USD Million
      3. By End Users- Market Size & Forecast 2018-2028F, USD Million
      4. By Distribution Channel- Market Size & Forecast 2018-2028F, USD Million
      5. By Company- Market Size & Forecast 2018-2028F, USD Million
      6. By Country
        1. Brazil
        2. Argentina
        3. Rest of South America
    3. Brazil Cyanotic Heart Disease Market Analysis (2018-2028F)
      1. By Treatment Type- Market Size & Forecast 2018-2028F, USD Million
      2. By End Users- Market Size & Forecast 2018-2028F, USD Million
    4. Argentina Cyanotic Heart Disease Market Analysis (2018-2028F)
      1. By Treatment Type- Market Size & Forecast 2018-2028F, USD Million
      2. By End Users- Market Size & Forecast 2018-2028F, USD Million
  13. Europe Cyanotic Heart Disease Market Analysis (2018-2028F)
    1. Market Size & Analysis
      1. Market Revenues (USD Million)
    2. Market Share & Analysis
      1. By Treatment Type- Market Size & Forecast 2018-2028F, USD Million
      2. By Route of Administration- Market Size & Forecast 2018-2028F, USD Million
      3. By End Users- Market Size & Forecast 2018-2028F, USD Million
      4. By Distribution Channel- Market Size & Forecast 2018-2028F, USD Million
      5. By Company- Market Size & Forecast 2018-2028F, USD Million
      6. By Country
        1. Germany
        2. The UK
        3. France
        4. Spain
        5. Italy
        6. Rest of Europe
    3. Germany Cyanotic Heart Disease Market Analysis (2018-2028F)
      1. By Treatment Type- Market Size & Forecast 2018-2028F, USD Million
      2. By End Users- Market Size & Forecast 2018-2028F, USD Million
    4. France Cyanotic Heart Disease Market Analysis (2018-2028F)
      1. By Treatment Type- Market Size & Forecast 2018-2028F, USD Million
      2. By End Users- Market Size & Forecast 2018-2028F, USD Million
    5. The UK Cyanotic Heart Disease Market Analysis (2018-2028F)
      1. By Treatment Type- Market Size & Forecast 2018-2028F, USD Million
      2. By End Users- Market Size & Forecast 2018-2028F, USD Million
    6. Spain Cyanotic Heart Disease Market Analysis (2018-2028F)
      1. By Treatment Type- Market Size & Forecast 2018-2028F, USD Million
      2. By End Users- Market Size & Forecast 2018-2028F, USD Million
    7. Italy Cyanotic Heart Disease Market Analysis (2018-2028F)
      1. By Treatment Type- Market Size & Forecast 2018-2028F, USD Million
      2. By End Users- Market Size & Forecast 2018-2028F, USD Million
  14. The Middle East & Africa Cyanotic Heart Disease Market Analysis (2018-2028F)
    1. Market Size & Analysis
      1. Market Revenues (USD Million)
    2. Market Share & Analysis
      1. By Treatment Type- Market Size & Forecast 2018-2028F, USD Million
      2. By Route of Administration- Market Size & Forecast 2018-2028F, USD Million
      3. By End Users- Market Size & Forecast 2018-2028F, USD Million
      4. By Distribution Channel- Market Size & Forecast 2018-2028F, USD Million
      5. By Company- Market Size & Forecast 2018-2028F, USD Million
      6. By Country
        1. The UAE
        2. Saudi Arabia
        3. Qatar
        4. Egypt
        5. South Africa
        6. Rest of the Middle East & Africa
    3. The UAE Cyanotic Heart Disease Market Analysis (2018-2028F)
      1. By Treatment Type- Market Size & Forecast 2018-2028F, USD Million
      2. By End Users- Market Size & Forecast 2018-2028F, USD Million
    4. Saudi Arabia Cyanotic Heart Disease Market Analysis (2018-2028F)
      1. By Treatment Type- Market Size & Forecast 2018-2028F, USD Million
      2. By End Users- Market Size & Forecast 2018-2028F, USD Million
    5. Qatar Cyanotic Heart Disease Market Analysis (2018-2028F)
      1. By Treatment Type- Market Size & Forecast 2018-2028F, USD Million
      2. By End Users- Market Size & Forecast 2018-2028F, USD Million
    6. Egypt Cyanotic Heart Disease Market Analysis (2018-2028F)
      1. By Treatment Type- Market Size & Forecast 2018-2028F, USD Million
      2. By End Users- Market Size & Forecast 2018-2028F, USD Million
    7. South Africa Cyanotic Heart Disease Market Analysis (2018-2028F)
      1. By Treatment Type- Market Size & Forecast 2018-2028F, USD Million
      2. By End Users- Market Size & Forecast 2018-2028F, USD Million
  15. Asia-Pacific Cyanotic Heart Disease Market Analysis (2018-2028F)
    1. Market Size & Analysis
      1. Market Revenues (USD Million)
    2. Market Share & Analysis
      1. By Treatment Type- Market Size & Forecast 2018-2028F, USD Million
      2. By Route of Administration- Market Size & Forecast 2018-2028F, USD Million
      3. By End Users- Market Size & Forecast 2018-2028F, USD Million
      4. By Distribution Channel- Market Size & Forecast 2018-2028F, USD Million
      5. By Company- Market Size & Forecast 2018-2028F, USD Million
      6. By Country
        1. China
        2. India
        3. Japan
        4. South Korea
        5. Australia
        6. Rest of Asia-Pacific
    3. China Cyanotic Heart Disease Market Analysis (2018-2028F)
      1. By Treatment Type- Market Size & Forecast 2018-2028F, USD Million
      2. By End Users- Market Size & Forecast 2018-2028F, USD Million
    4. India Cyanotic Heart Disease Market Analysis (2018-2028F)
      1. By Treatment Type- Market Size & Forecast 2018-2028F, USD Million
      2. By End Users- Market Size & Forecast 2018-2028F, USD Million
    5. Japan Cyanotic Heart Disease Market Analysis (2018-2028F)
      1. By Treatment Type- Market Size & Forecast 2018-2028F, USD Million
      2. By End Users- Market Size & Forecast 2018-2028F, USD Million
    6. South Korea Cyanotic Heart Disease Market Analysis (2018-2028F)
      1. By Treatment Type- Market Size & Forecast 2018-2028F, USD Million
      2. By End Users- Market Size & Forecast 2018-2028F, USD Million
    7. Australia Cyanotic Heart Disease Market Analysis (2018-2028F)
      1. By Treatment Type- Market Size & Forecast 2018-2028F, USD Million
      2. By End Users- Market Size & Forecast 2018-2028F, USD Million
  16. Competitive Benchmarking & Company Profiles
    1. Competition Matrix
      1. Product Portfolio
      2. Target Markets
      3. Target End Users
      4. Research & Development
      5. Strategic Alliances
      6. Strategic Initiatives
    2. Company Profiles (Business Description, Product Offering, Strategic Alliances or Partnerships, etc)
      1. Cipla Inc
        1. Business Description
        2. Product Portfolio
        3. Strategic Alliances or Partnerships
        4. Recent Developments
        5. Financial Details
        6. Others
      2. Amneal Pharmaceutical LLC
        1. Business Description
        2. Product Portfolio
        3. Strategic Alliances or Partnerships
        4. Recent Developments
        5. Financial Details
        6. Others
      3. Bausch Health Companies Inc.
        1. Business Description
        2. Product Portfolio
        3. Strategic Alliances or Partnerships
        4. Recent Developments
        5. Financial Details
        6. Others
      4. Pfizer Inc
        1. Business Description
        2. Product Portfolio
        3. Strategic Alliances or Partnerships
        4. Recent Developments
        5. Financial Details
        6. Others
      5. Hikma Pharmaceuticals Plc
        1. Business Description
        2. Product Portfolio
        3. Strategic Alliances or Partnerships
        4. Recent Developments
        5. Financial Details
        6. Others
      6. Eton Biotech Pvt. Ltd
        1. Business Description
        2. Product Portfolio
        3. Strategic Alliances or Partnerships
        4. Recent Developments
        5. Financial Details
        6. Others
      7. Norvartis AG
        1. Business Description
        2. Product Portfolio
        3. Strategic Alliances or Partnerships
        4. Recent Developments
        5. Financial Details
        6. Others
      8. Johnsons & Johnsons Services Inc
        1. Business Description
        2. Product Portfolio
        3. Strategic Alliances or Partnerships
        4. Recent Developments
        5. Financial Details
        6. Others
      9. Teva Pharmaceutical Industries Ltd
        1. Business Description
        2. Product Portfolio
        3. Strategic Alliances or Partnerships
        4. Recent Developments
        5. Financial Details
        6. Others
      10. Others
        1. Business Description
        2. Product Portfolio
        3. Strategic Alliances or Partnerships
        4. Recent Developments
        5. Financial Details
        6. Others
  17. About Us & Disclaimer


Cyanotic Heart Disease Market Segmentation Slide